- Stocks
- Healthcare
- NASDAQ: ADPT

Price (delayed)

$4.3

Market cap

$633.68M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.49

Enterprise value

$787.53M

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the

ADPT's debt is down by 2% year-on-year

The gross profit has declined by 18% year-on-year but it has grown by 5% since the previous quarter

The gross margin has declined by 13% year-on-year but it is up by 2.7% since the previous quarter

ADPT's equity is down by 35% year-on-year and by 11% since the previous quarter

The quick ratio has declined by 19% year-on-year and by 3% since the previous quarter

What are the main financial stats of ADPT

Market
Valuations
Earnings

Shares outstanding

147.37M

Market cap

$633.68M

Enterprise value

$787.53M

Price to earnings (P/E)

N/A

Price to book (P/B)

2.27

Price to sales (P/S)

3.59

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

4.51

Revenue

$174.5M

EBIT

-$201.8M

EBITDA

-$173.29M

Free cash flow

-$144.81M

Per share
Balance sheet
Liquidity

EPS

-$1.49

Free cash flow per share

-$0.99

Book value per share

$1.89

Revenue per share

$1.2

TBVPS

$3.41

Total assets

$620.32M

Total liabilities

$345.56M

Debt

$228.04M

Equity

$274.91M

Working capital

$291.08M

Debt to equity

0.83

Current ratio

4.51

Quick ratio

4.27

Net debt/EBITDA

-0.89

Margins
Efficiency
Dividend

EBITDA margin

-99.3%

Gross margin

57.1%

Net margin

-123.2%

Operating margin

-125.3%

Return on assets

-31.1%

Return on equity

-64.1%

Return on invested capital

-32.5%

Return on capital employed

-37.6%

Return on sales

-115.6%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Adaptive Biotechnologies stock price performed over time

Intraday

-3.37%

1 week

-4.66%

1 month

27.6%

1 year

-45.98%

YTD

-12.24%

QTD

18.78%

How have Adaptive Biotechnologies's revenue and profit performed over time

Revenue

$174.5M

Gross profit

$99.58M

Operating income

-$218.6M

Net income

-$215.06M

Gross margin

57.1%

Net margin

-123.2%

Adaptive Biotechnologies's operating margin has decreased by 19% YoY but it has increased by 6% QoQ

The gross profit has declined by 18% year-on-year but it has grown by 5% since the previous quarter

ADPT's net margin is down by 16% year-on-year but it is up by 7% since the previous quarter

The gross margin has declined by 13% year-on-year but it is up by 2.7% since the previous quarter

What is Adaptive Biotechnologies's growth rate over time

What is Adaptive Biotechnologies stock price valuation

P/E

N/A

P/B

2.27

P/S

3.59

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

4.51

ADPT's EPS is down by 9% year-on-year but it is up by 4.5% since the previous quarter

ADPT's P/B is 58% below its 5-year quarterly average of 5.4 but 3.2% above its last 4 quarters average of 2.2

ADPT's equity is down by 35% year-on-year and by 11% since the previous quarter

ADPT's price to sales (P/S) is 87% lower than its 5-year quarterly average of 28.0 and 12% lower than its last 4 quarters average of 4.1

The revenue has contracted by 5% YoY but it has grown by 2.5% from the previous quarter

How efficient is Adaptive Biotechnologies business performance

The ROE has shrunk by 56% YoY and by 6% QoQ

Adaptive Biotechnologies's ROA has decreased by 33% YoY

The ROIC has contracted by 19% YoY

ADPT's return on sales is down by 14% year-on-year but it is up by 7% since the previous quarter

What is ADPT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ADPT.

How did Adaptive Biotechnologies financials performed over time

The total assets is 80% more than the total liabilities

The total assets has contracted by 22% YoY and by 6% from the previous quarter

The quick ratio has declined by 19% year-on-year and by 3% since the previous quarter

ADPT's debt is 17% smaller than its equity

ADPT's debt to equity has surged by 51% year-on-year and by 12% since the previous quarter

ADPT's equity is down by 35% year-on-year and by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.